genetics
-
DATABASE (4)
-
ARTICLES (6)
Digital health startup offering genotyping tests and analysis using AI for personal cardiovascular, pharmaco and wellness (diet and fitness) genetics-based predictions and health guidelines.
Digital health startup offering genotyping tests and analysis using AI for personal cardiovascular, pharmaco and wellness (diet and fitness) genetics-based predictions and health guidelines.
Founded in 2012 in San Francisco, Joyance invests in the “vectors of happiness” that it classifies as areas of science, including genetics and bioscience, the microbiome, neuroscience, virtual and augmented reality, and foodtech. It also invests in the area of social networking. Its investments are made through its management company, Ataraxia, and many have a European focus. It currently has 115 companies in its portfolio, with recent investments including in the August 2021 $3.6m seed round of Polish bionic limb manufacturer and in the July 2021 $8m Series A round of Israeli sports injury AI platform Zone7.
Founded in 2012 in San Francisco, Joyance invests in the “vectors of happiness” that it classifies as areas of science, including genetics and bioscience, the microbiome, neuroscience, virtual and augmented reality, and foodtech. It also invests in the area of social networking. Its investments are made through its management company, Ataraxia, and many have a European focus. It currently has 115 companies in its portfolio, with recent investments including in the August 2021 $3.6m seed round of Polish bionic limb manufacturer and in the July 2021 $8m Series A round of Israeli sports injury AI platform Zone7.
Senior Scientific Advisor and co-founder of The Not Company (NotCo)
Pablo Zamora is a biotechnologist from the University of Santiago, where he worked as a professor and research scientist until 2008. In 2009, he started his postdoctoral research on Mexico’s maize genetics at UC Davis Life Science Innovation Center. He worked there as a senior scientist and associate until 2014. In 2015, he was appointed the center’s Chief Science Officer based in Chile, a position he was in till January 2018.From 2013–2015, he also worked on various plant and microbe genomics projects as a senior scientist in Mars Advanced Research Institute. He was also an editor from 2012–2017 at the Journal of Technology Management & Innovation and worked at the non-profit PIPRA from 2010–2018 as international alliance manager in Sacramento, University of California.In 2015, he co-founded The Not Company (NotCo) based in Santiago. He was appointed CSO in February 2018, a role he led until March 2020, when he left the company to focus on a new project, AptaBuilder, a $60m program that promotes R&D for Chilean technology-based ventures. Zamora still consults as NotCo’s senior scientific advisor.
Pablo Zamora is a biotechnologist from the University of Santiago, where he worked as a professor and research scientist until 2008. In 2009, he started his postdoctoral research on Mexico’s maize genetics at UC Davis Life Science Innovation Center. He worked there as a senior scientist and associate until 2014. In 2015, he was appointed the center’s Chief Science Officer based in Chile, a position he was in till January 2018.From 2013–2015, he also worked on various plant and microbe genomics projects as a senior scientist in Mars Advanced Research Institute. He was also an editor from 2012–2017 at the Journal of Technology Management & Innovation and worked at the non-profit PIPRA from 2010–2018 as international alliance manager in Sacramento, University of California.In 2015, he co-founded The Not Company (NotCo) based in Santiago. He was appointed CSO in February 2018, a role he led until March 2020, when he left the company to focus on a new project, AptaBuilder, a $60m program that promotes R&D for Chilean technology-based ventures. Zamora still consults as NotCo’s senior scientific advisor.
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
HeartGenetics: Using genetic data and AI to improve predictive health outcomes
Amid growing demand for personalized health and wellness solutions, the Portuguese startup is seeking €2m to expand to Germany and the UK
Intudo Ventures: Grooming returning overseas talent for an Indonesia-only bet
Combining the experience and networks of foreign-educated Indonesians with local distribution channels, Intudo’s hyperlocal strategy has attracted $200m in managed assets
Future Food Asia: Temasek, Continental Grain on investing in agrifood in Singapore and China
The two heavyweight investors discuss opportunities, needs and how agrifood startups can scale in Asian markets
Smart Agrifood Summit 2019 big winner Agri Marketplace makes fair trade easy
Winner of Best Startup and Best Innovative Agrifood Startup, Agri Marketplace presented its fast, transparent and interconnected crop trading platform at Málaga Smart Agrifood Summit 2019
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
Animal AgTech Innovation Summit 2021: Experts discuss post-pandemic priorities
The pandemic not only put digital tech in everyone’s hands, it also forced thinking about collecting meaningful data and moving it on-demand to both producers and decision makers
Sorry, we couldn’t find any matches for “genetics”.
POPULAR DATABASE
